Advertisement

Inflammation

, Volume 33, Issue 6, pp 353–358 | Cite as

The ApoB/ApoA1 Ratio is Associated with Metabolic Syndrome and its Components in a Chinese Population

  • Li Zhong
  • Qifu LiEmail author
  • Yuanjuan Jiang
  • Dan Cheng
  • Zhoujun Liu
  • Bangqiong Wang
  • Rong Luo
  • Qingfeng Cheng
  • Hua Qing
Article

Abstract

In this study, we assessed whether the apolipoprotein B/apolipoprotein A1 ratio (ApoB/ApoA1) is related to metabolic syndrome (MS) and its components in an urban Chinese population. A total of 709 community residents were enrolled. Metabolic syndrome was defined according to the International Diabetes Federation definition in 2005. The high ApoB/ApoA1 group was defined as the gender-specific upper quartile of the ApoB/ApoA1 ratio. Insulin resistance (IR) was defined as the upper quartile of Homa-IR. The ApoB/ApoA1 ratio was significantly higher in subjects with MS, compared to those without (p < 0.05). After adjusting for age and gender, subjects with MS (odds ratio [OR] = 3.5) or IR (OR = 2.3) were more likely to be in the high ApoB/ApoA1 group. The ApoB/ApoA1 ratio increased significantly as the number of MS components increased (p < 0.05). Taken together, these data demonstrate that the ApoB/ApoA1 ratio is strongly associated with MS and its components in an urban Chinese population.

KEY WORDS

ApoB ApoA1 ApoB/ApoA1 ratio metabolic syndrome insulin resistance 

References

  1. 1.
    Alberti, K.G., P. Zimmet, J. Shaw, and IDF Epidemiology Task Force Consensus Group. 2005. The metabolic syndrome—a new worldwide definition. Lancet 366: 1059–1062.CrossRefPubMedGoogle Scholar
  2. 2.
    International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. Available from http://www.idf.org/webdata/docs/MetS _def_update2006.pdf
  3. 3.
    Elovson, J., J.E. Chatterton, G.T. Bell, V.N. Schumaker, M.A. Reuben, D.L. Puppione, J.R. Reeve, and N.L. Young. 1988. Plasma very low density lipoproteins contain a single molecule of apolipoprotein B. Journal of Lipid Research 29: 1461–1473.PubMedGoogle Scholar
  4. 4.
    Walldius, G., I. Jungner, A.H. Aastveit, I. Holme, C.D. Furberg, and A.D. Sniderman. 2004. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clinical Chemistry and Laboratory Medicine 42: 1355–1363.CrossRefPubMedGoogle Scholar
  5. 5.
    Walldius, G., and I. Jungner. 2006. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy—a review of the evidence. Journal of Internal Medicine 259: 493–519.CrossRefPubMedGoogle Scholar
  6. 6.
    Walldius, G., I. Jungner, I. Holme, A.H. Aastveit, W. Kolar, and E. Steiner. 2001. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358: 2026–2033.CrossRefPubMedGoogle Scholar
  7. 7.
    Yusuf, S., S. Hawken, S. Ounpuu, T. Dans, A. Avezum, F. Lanas, M. McQueen, A. Budaj, P. Pais, J. Varigos, L. Lisheng, and INTERHEART Study Investigators. 2004. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364: 937–952.CrossRefPubMedGoogle Scholar
  8. 8.
    van der Steeg, W.A., S.M. Boekholdt, E.A. Stein, K. El-Harchaoui, E.S. Stroes, M.S. Sandhu, N.J. Wareham, J.W. Jukema, R. Luben, A.H. Zwinderman, J.J. Kastelein, and K.T. Khaw. 2007. Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk. Annals of Internal Medicine 146: 640–648.PubMedGoogle Scholar
  9. 9.
    Dunder, K., L. Lind, B. Zethelius, L. Berglund, and H. Lithell. 2004. Evaluation of a scoring scheme, including proinsulin and the apolipoprotein B/apolipoprotein A1 ratio, for the risk of acute coronary events in middle-aged men: Uppsala Longitudinal Study of Adult Men (ULSAM). American Heart Journal 148: 596–601.CrossRefPubMedGoogle Scholar
  10. 10.
    Meisinger, C., H. Loewel, W. Mraz, and W. Koenig. 2005. Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study. European Heart Journal 26: 271–278.CrossRefPubMedGoogle Scholar
  11. 11.
    Sierra-Johnson, J., A. Romero-Corral, V.K. Somers, F. Lopez-Jimenez, G. Walldius, A. Hamsten, M.L. Hellénius, and R.M. Fisher. 2007. ApoB/apoA-I ratio: an independent predictor of insulin resistance in US non-diabetic subjects. European Heart Journal 28: 2637–2643.CrossRefPubMedGoogle Scholar
  12. 12.
    Matthews, D.R., J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, and R.C. Turner. 1985. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412–419.CrossRefPubMedGoogle Scholar
  13. 13.
    Relimpio, F., F. Losada, A. Pumar, M.A. Mangas, F. Morales, and R. Astorga. 2002. Relationships of apolipoprotein B(100) with the metabolic syndrome in type 2 diabetes mellitus. Diabetes Research and Clinical Practice 57: 199–207.CrossRefPubMedGoogle Scholar
  14. 14.
    Muntner, P., J. He, J. Chen, V. Fonseca, and P.K. Whelton. 2004. Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III). Annals of Epidemiology 14: 686–695.CrossRefPubMedGoogle Scholar
  15. 15.
    Onat, A., G. Can, G. Hergenç, M. Yazici, A. Karabulut, and S. Albayrak. 2007. Serum apolipoprotein B predicts dyslipidemia, metabolic syndrome and, in women, hypertension and diabetes, independent of markers of central obesity and inflammation. International Journal of Obesity 31: 1119–1125.CrossRefPubMedGoogle Scholar
  16. 16.
    Wallenfeldt, K., L. Bokemark, J. Wikstrand, J. Hulthe, and B. Fagerberg. 2004. Apolipoprotein B/apolipoprotein A-I in relation to the metabolic syndrome and change in carotid artery intima-media thickness during 3 years in middle-aged men. Stroke 35: 2248–2252.CrossRefPubMedGoogle Scholar
  17. 17.
    Lind, L., B. Vessby, and J. Sundström. 2006. The apolipoprotein B/AI ratio and the metabolic syndrome independently predict risk for myocardial infarction in middle-aged men. Arteriosclerosis, Thrombosis, and Vascular Biology 26: 406–410.CrossRefPubMedGoogle Scholar
  18. 18.
    Sierra-Johnson, J., V.K. Somers, F.H. Kuniyoshi, C.A. Garza, W.L. Isley, A.S. Gami, and F. Lopez-Jimenez. 2006. Comparison of apolipoprotein-B/apolipoprotein-AI in subjects with versus without the metabolic syndrome. American Journal of Cardiology 98: 1369–1373.CrossRefPubMedGoogle Scholar
  19. 19.
    Zhao, W.H., J. Zhang, Y. You, Q.Q. Man, H. Li, C.R. Wang, Y. Zhai, Y. Li, S.G. Jin, and X.G. Yang. 2005. Epidemiologic characteristics of dyslipidemia in people aged 18 years and over in China. Zhonghua Yu Fang Yi Xue Za Zhi. 39: 306–310 (In Chinese).PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Li Zhong
    • 1
  • Qifu Li
    • 1
    Email author
  • Yuanjuan Jiang
    • 1
  • Dan Cheng
    • 1
  • Zhoujun Liu
    • 1
  • Bangqiong Wang
    • 1
  • Rong Luo
    • 2
  • Qingfeng Cheng
    • 1
  • Hua Qing
    • 1
  1. 1.Department of EndocrinologyThe First Affiliated Hospital of Chongqing Medical UniversityChongqingChina
  2. 2.Medical Examination CenterThe First Affiliated Hospital of Chongqing Medical UniversityChongqingChina

Personalised recommendations